SSRI medications during pregnancy may increase risk of gestational diabetes but protect against preterm birth
Medical Xpress
February 13, 2026
AI-Generated Deep Dive Summary
An international study reveals that the use of selective serotonin reuptake inhibitor (SSRI) antidepressants during pregnancy carries dual implications. While SSRIs may reduce the risks of preterm birth and low birth weight, they are also linked to an increased risk of gestational diabetes and early adaptation challenges in newborns. This finding is significant as it highlights the need for careful consideration when weighing the benefits and potential drawbacks of SSRI use during pregnancy.
The study, published in *American Journal of Obstetrics & Gynecology MFM*, analyzed data from a large cohort of pregnancies to isolate the effects of SSRIs independent of maternal depression. Researchers found that SSRI exposure was associated with gestational diabetes, possibly due to metabolic changes or hormonal disruptions caused by the medications. Additionally, newborns exposed to SSRIs were observed to have early adaptation difficulties, underscoring the importance of understanding how these drugs impact both mother and child.
On the other hand, the study also found that SSRI use during pregnancy was linked to a reduced likelihood of preterm birth and low birth weight. This dual effect underscores the complexity of balancing mental health care with potential physical risks in pregnancy. For women considering SSRI use while pregnant, this research emphasizes the importance of discussing individualized treatment plans with healthcare providers.
The findings are particularly relevant for expectant mothers and healthcare providers, as they highlight the need to weigh the benefits of treating maternal depression against potential risks. While SSR
Verticals
healthmedical
Originally published on Medical Xpress on 2/13/2026